immunotherapy

January 14, 2022

Vanderbilt biostatisticians launch Cancer-Immu data portal for predicting response to immune checkpoint blockade immunotherapy

A new data portal called Cancer-Immu established by a team of Vanderbilt University Medical Center biostatisticians can help cancer clinicians and researchers predict which patients will respond to immune checkpoint inhibitors.

By Tom Wilemon
September 10, 2021

Novel immunotherapy shows robust response for multiple myeloma

Vanderbilt research found that a novel immunotherapy demonstrated robust effectiveness in treating relapsed or refractory multiple myeloma.

By Tom Wilemon
August 12, 2021

Study identifies biomarker for breast cancer response to immunotherapy

A biomarker that has proven to be a predictor for response to immunotherapies in melanoma patients also has clinical relevance for breast cancer patients, according to a new study published in Clinical Cancer Research, a journal of the American Association for Cancer Research.

By Tom Wilemon
August 5, 2021

Clinical trial to test immunotherapy for rectal cancer

A new clinical trial seeks to determine whether immunotherapy in combination with short-course radiation followed by surgical resection could be a curative treatment for locally advanced rectal cancer.

By Tom Wilemon
July 1, 2021

Preclinical study supports rigosertib as booster to immunotherapy treatment for melanoma

A team of Vanderbilt researchers have shown in a preclinical study that the investigational drug rigosertib could be a potential booster treatment to elicit response to immunotherapies among melanoma patients.

By Tom Wilemon
April 15, 2021

Method proposed to correct misinterpretations of long-term survival rates for immunotherapies

Immune checkpoint inhibitors have transformed cancer care to the point where the popular Cox proportional-hazards model provides misleading estimates of the treatment effect, according to a new study published April 15 in JAMA Oncology.

By Tom Wilemon
April 1, 2021

Breast cancer cells ‘steal’ nutrients from immune cells: study

Triple-negative breast cancer cells engage in a “glutamine steal” — outcompeting T cells for the nutrient glutamine and impairing their ability to kill tumor cells, Vanderbilt researchers have discovered.
By Leigh MacMillan
March 25, 2021

Forty-three percent of melanoma patients have chronic complications from immunotherapies

Chronic side effects among melanoma survivors after treatment with anti-PD-1 immunotherapies are more common than previously recognized, according to a study published March 25 in JAMA Oncology.
By Tom Wilemon
December 22, 2020

Arthritis drug may treat immunotherapy-related heart complication

By Tom Wilemon
August 20, 2020

A “torque” for tumor blood vessels

Vanderbilt scientists have discovered a new target for normalizing tumor blood vessels to improve cancer immunotherapies.
By Bill Snyder
June 4, 2020

Potential new cancer target

Vanderbilt researchers have discovered the involvement of a certain type of adenosine receptor in mediating signaling that supports tumor growth and metastasis.
By Bill Snyder
February 27, 2020

Patient’s cancer treatment includes new immunotherapy

Dona Potter, 87, rode Harleys and drove 18-wheelers back when men dominated the open highways, and she is still defying expectations.
By Tom Wilemon
January 16, 2020

Journey Home Project supports first CAR-T infusion at VA hospital

The Tennessee Valley Healthcare System performed its first CAR-T infusion recently at the Veterans Administration hospital in Nashville.
By Tom Wilemon
1 2 3 4 5